TY - JOUR
T1 - Treatment of asthma with nebulized lidocaine
T2 - A randomized, placebo-controlled study
AU - Hunt, Loren W.
AU - Frigas, Evangelo
AU - Butterfield, Joseph H.
AU - Kita, Hirohito
AU - Blomgren, Judith
AU - Dunnette, Sandra L.
AU - Offord, Kenneth P.
AU - Gleich, Gerald J.
N1 - Funding Information:
Supported by grants from the National Institutes of Health, AI 34577, and from the Mayo Foundation.
PY - 2004/5
Y1 - 2004/5
N2 - Background: In 2 prior uncontrolled studies, nebulized lidocaine reduced oral glucocorticoid use in patients with severe glucocorticoid-dependent asthma. Objective: We tested the safety and efficacy of nebulized lidocalne in a randomized, placebo-controlled study in patients with mild-to-moderate asthma. Methods: We recruited 50 subjects (25 receiving lidocaine and 25 receiving placebo); all had a prebronchodilator FEV1 of 64% to 125% of predicted normal value and were treated with daily inhaled glucocorticoids (but not systemic glucocorticoids) and bronchodilators for at least 2 months. Before treatment, subjects monitored their symptoms and peak flow values and maintained their medications for 2 weeks. At initiation, subjects inhaled either nebulized placebo (saline) or lidocaine (4%, 100 mg) 4 times daily. All subjects were instructed to reduce their inhaled glucocorticoid dosage by one half each week for 3 weeks and to discontinue glucocorticoid treatment at week 4. The subjects continued the nebulized lidocaine or placebo for a total of 8 weeks, monitored their symptoms, and used bronchodilators to control symptoms. Results: Indicators of asthma severity showed benefit for the lidocaine-treated group: changes in FEV1 (P ≤ .001), nighttime awakenings (P ≤ .02), symptoms (P ≤ .010), bronchodilator use (P ≤ .010), and blood eosinophil counts (P ≤ .020). Subjects in both groups reduced use of inhaled glucocorticoids comparably. Subjects receiving nebulized placebo showed increases in their symptom scores, bronchodilator use (P ≤ .05 for both), and blood eosinophil counts (P ≤ .01) and decreases in FEV1 (P ≤ .001). Conclusion: Nebulized lidocaine provided effective and safe therapy in subjects with mild-to-moderate asthma.
AB - Background: In 2 prior uncontrolled studies, nebulized lidocaine reduced oral glucocorticoid use in patients with severe glucocorticoid-dependent asthma. Objective: We tested the safety and efficacy of nebulized lidocalne in a randomized, placebo-controlled study in patients with mild-to-moderate asthma. Methods: We recruited 50 subjects (25 receiving lidocaine and 25 receiving placebo); all had a prebronchodilator FEV1 of 64% to 125% of predicted normal value and were treated with daily inhaled glucocorticoids (but not systemic glucocorticoids) and bronchodilators for at least 2 months. Before treatment, subjects monitored their symptoms and peak flow values and maintained their medications for 2 weeks. At initiation, subjects inhaled either nebulized placebo (saline) or lidocaine (4%, 100 mg) 4 times daily. All subjects were instructed to reduce their inhaled glucocorticoid dosage by one half each week for 3 weeks and to discontinue glucocorticoid treatment at week 4. The subjects continued the nebulized lidocaine or placebo for a total of 8 weeks, monitored their symptoms, and used bronchodilators to control symptoms. Results: Indicators of asthma severity showed benefit for the lidocaine-treated group: changes in FEV1 (P ≤ .001), nighttime awakenings (P ≤ .02), symptoms (P ≤ .010), bronchodilator use (P ≤ .010), and blood eosinophil counts (P ≤ .020). Subjects in both groups reduced use of inhaled glucocorticoids comparably. Subjects receiving nebulized placebo showed increases in their symptom scores, bronchodilator use (P ≤ .05 for both), and blood eosinophil counts (P ≤ .01) and decreases in FEV1 (P ≤ .001). Conclusion: Nebulized lidocaine provided effective and safe therapy in subjects with mild-to-moderate asthma.
KW - Asthma
KW - Eosinophils
KW - Glucocorticoids
KW - Lidocaine
UR - http://www.scopus.com/inward/record.url?scp=2342476447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=2342476447&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2004.02.039
DO - 10.1016/j.jaci.2004.02.039
M3 - Article
C2 - 15131566
AN - SCOPUS:2342476447
SN - 0091-6749
VL - 113
SP - 853
EP - 859
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 5
ER -